Buy Rating Affirmed for 908 Devices on Strong Market Position and Growth Prospects
TD Cowen Maintains 908 Devices(MASS.US) With Buy Rating
Stephens & Co. : The 908 Devices (MASS.US) rating was confirmed and adjusted from an increase to an increase in holdings rating, with a target price of $14.00.
908 Devices Analyst Ratings
Stephens & Co. Reiterates Overweight on 908 Devices, Maintains $14 Price Target
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Aurinia Pharmaceuticals (AUPH) and 908 Devices (MASS)
Buy Rating Affirmed for 908 Devices Amidst PAT Growth and Solid Financial Outlook
Stifel Nicolaus Remains a Buy on 908 Devices (MASS)
Stephens & Co. Reiterates Overweight on 908 Devices, Maintains $14 Price Target
908 Devices Analyst Ratings
908 Devices (MASS) Receives a Buy From SVB Securities
908 Devices Analyst Ratings
Stephens & Co. Initiates Coverage On 908 Devices With Overweight Rating, Announces Price Target of $14
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), 908 Devices (MASS) and Privia Health Group (PRVA)
SVB Securities Sticks to Its Buy Rating for 908 Devices (MASS)
SVB Securities Adjusts 908 Devices' Price Target to $20 From $30, Keeps Outperform Rating
908 Devices Analyst Ratings
SVB Securities Keeps Their Buy Rating on 908 Devices (MASS)
908 Devices Analyst Ratings